PharmacoEconomics

ISSNs: 1170-7690, 1179-2027

Additional searchable ISSN (Electronic): 1179-2027

Adis International Ltd

Scopus rating (2020): CiteScore 6.4 SJR 1.809 SNIP 1.822

Journal

Publications

1 - 25 out of 143Page size: 25
RSS feed of this list
  1. 2022

  2. Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real-world data: opportunities and challenges

    Gomes, M., Latimer, N., Soares, M. O., Dias, S., Baio, G., Freemantle, N., Dawoud, D., Wailoo, A. & Grieve, R., 25 Mar 2022, (E-pub ahead of print)

    Article in PharmacoEconomics

  3. 2021

  4. Developing the EQ-5D-5L value set for Uganda using the ‘lite’ protocol

    Yang, F., Katumba, K. R., Roudijk, B., Yang, Z., Revill, P., Griffin, S., Ochanda, P. N., Lamorde, M., Greco, G., Seeley, J. & Sculpher, M., 29 Nov 2021, (E-pub ahead of print)

    Article in PharmacoEconomics

  5. Factors limiting subgroup analysis in cost-effectiveness analysis and a call for transparency

    Shields, G., Wilberforce, M. R., Clarkson, P., Farragher, T., Verma, A. & Davies, L., 29 Oct 2021, (E-pub ahead of print)

    Article in PharmacoEconomics

  6. The relevance of including future health care costs in cost-effectiveness threshold calculations for for the UK NHS

    Perry-Duxbury, M., Lomas, J., Asaria, M. & van Baal, P., 26 Oct 2021, (E-pub ahead of print)

    Article in PharmacoEconomics

  7. Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates

    Edney, L., Lomas, J., Karnon, J., Vallejo-Torres, L., Stadhouders, N., Siverskog, J., Paulden, M., Edoka, I. P. & Ochalek, J. M., 29 Sep 2021, (E-pub ahead of print)

    Article in PharmacoEconomics

  8. Jointly modelling economics and epidemiology to support public policy decisions for the COVID-19 response: a review of UK studies

    Duarte, A. I., Walker, S. M., Metry, A., Wong, R., Panovska-Griffiths, J. & Sculpher, M., 19 Jun 2021

    Article in Pharmacoeconomics

  9. 2020

  10. Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach

    Ochalek, J. M., Wang, H., Gu, Y., Lomas, J., Cutler, H. & Jin, C., 28 Aug 2020, (E-pub ahead of print)

    Article in PharmacoEconomics

  11. Conducting value for money analyses for non-randomised interventional studies including service evaluations: an educational review with recommendations

    Franklin, M., Lomas, J. & Richardson, G., 15 Apr 2020, (E-pub ahead of print)

    Article in PharmacoEconomics

  12. ‘Mapping’ health state utility values from non-preference-based measures: a systematic literature review in rare diseases

    Meregaglia, M., Whittal, A., Nicod, E. & Drummond, M. F., 10 Mar 2020, (E-pub ahead of print)

    Article in Pharmacoeconomics

  13. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

    Sculpher, M. & Palmer, S., 13 Jan 2020, (E-pub ahead of print)

    Article in PharmacoEconomics

  14. 2019

  15. The Clinical and Cost-Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia: an Evidence Review Group Evaluation of a NICE Single Technology Appraisal: Inotuzumab for the treatment of adult R/R B-cell ALL: an ERG perspective

    Cox, E. M., Wade, R. F., Peron, M. M. G., Dietz, K. C., Eastwood, A. J., Palmer, S. J. & Griffin, S., 1 Sep 2019

    Article in PharmacoEconomics

  16. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

    Claxton, L., O'Connor, J., Woolacott, N., Wright, K. & Hodgson, R., 1 May 2019

    Review article in PharmacoEconomics

  17. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Walton, M., Sharif, S., Simmonds, M., Claxton, L. & Hodgson, R., 13 Apr 2019

    Review article in PharmacoEconomics

  18. Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities

    Keeney, E., Dawoud, D. & Dias, S., 9 Mar 2019, (E-pub ahead of print)

    Article in PharmacoEconomics

  19. An educational review about using cost data for the purpose of cost-effectiveness analysis

    Franklin, M., Lomas, J. R. S., Walker, S. M. & Young, T., 23 Jan 2019, (Accepted/In press)

    Article in PharmacoEconomics

  20. Brodalumab for the treatment of moderate to severe plaque psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

    Wade, R., Grosso, A., South, E., Rothery, C., Saramago, P., Schmitt, L., Wright, K. & Palmer, S., 22 Jan 2019

    Article in Pharmacoeconomics

  21. 2018

  22. The Future of Precision Medicine: Potential Impacts for Health Technology Assessment

    Love-Koh, J., Peel, A., Rejon-Parilla, J. C., Ennis, K., Lovett, R., Manca, A., Chalkidou, A., Wood, H. & Taylor, M., 21 Nov 2018

    Article in Pharmacoeconomics

  23. Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial

    Leurent, B., Gomes, M., Faria, R., Morris, S., Grieve, R. & Carpenter, J. R., Aug 2018

    Article in PharmacoEconomics

  24. Model structuring for economic evaluations of new health technologies

    Haji Ali Afzali, H., Bojke, L. & Karnon, J., 20 Jul 2018, (E-pub ahead of print)

    Article in Pharmacoeconomics.

  25. Discounting in Economic Evaluations

    Attema, A. E., Brouwer, W. B. F. & Claxton, K., 19 May 2018, (E-pub ahead of print)

    Review article in PharmacoEconomics

  26. Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities

    Keeney, E., Dawoud, D. & Dias, S., May 2018

    Article in Pharmacoeconomics

  27. Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review

    Ghijben, P., Gu, Y., Lancsar, E. & Zavarsek, S., Mar 2018

    Article in Pharmacoeconomics.

  28. Cost effectiveness thresholds: the past, the present and the future

    Thokala, P., Ochalek, J. M., Leech, A. & Tong, T., 9 Feb 2018

    Article in PharmacoEconomics

  29. 2017

  30. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Hodgson, R., Walton, M., Biswas, M., Mebrahtu, T. & Woolacott, N., 30 Nov 2017, (E-pub ahead of print)

    Article in PharmacoEconomics

  31. Informing reimbursement decisions using cost-effectiveness modelling: a guide to the process of generating elicited priors to capture model uncertainties

    Bojke, L., Grigore, B., Jankovic, D., Peters, J., Soares, M. F. O. & Stein, K., 1 Sep 2017

    Article in Pharmacoeconomics

Previous 1 2 3 4 5 6 Next

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations

York staff: edit these data